Skip to main content
SpringerLink
Log in

CRISPResso2 provides accurate and rapid genome editing sequence analysis

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Novel features of CRISPResso2.

Code availability

CRISPResso2 is available online at http://crispresso2.pinellolab.org, where users can run up to four samples simultaneously. The command line version without any limitations and with additional tools is available as a Docker image at https://hub.docker.com/r/pinellolab/crispresso2/ (Supplementary Note 4). The source code is available as Supplementary Software and online at https://github.com/pinellolab/CRISPResso2.

Data availability

Fig. 1a–c shows data available as SRR3305546 (untreated), SRR3305543 (BE1), SRR3305544 (BE2) and SRR3305545 (BE3)2. Figure 1d shows data obtained from the authors of ref. 10.

References

  1. Tsai, S. Q. & Joung, J. K. Nat. Rev. Genet. 17, 300–312 (2016).

    Article  CAS  Google Scholar 

  2. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Nature 533, 420–424 (2016).

    Article  CAS  Google Scholar 

  3. Komor, A.C. et al. Sci. Adv. 3, eaao4774 (2017).

  4. Kim, Y. B. et al. Nat. Biotechnol. 35, 371–376 (2017).

    Article  CAS  Google Scholar 

  5. Akcakaya, P. et al. Nature 561, 416–419 (2018).

  6. Pinello, L. et al. Nat. Biotechnol. 34, 695–697 (2016).

    Article  CAS  Google Scholar 

  7. Wang, X. et al. Bioinformatics 33, 3811–3812 (2017).

    Article  CAS  Google Scholar 

  8. Park, J., Lim, K., Kim, J.-S. & Bae, S. Bioinformatics 33, 286–288 (2017).

    Article  CAS  Google Scholar 

  9. Lindsay, H. et al. Nat. Biotechnol. 34, 701–702 (2016).

    Article  CAS  Google Scholar 

  10. Li, P. et al. CRISPR J. 1, 55–64 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

D.R.L. is supported by DARPA HR0011-17-2-0049; US NIH RM1 HG009490, R01 EB022376 and R35 GM118062; and the HHMI. J.K.J. is supported by DARPA HR0011-17-2-0042, NIH R35 GM118158 and NIH RM1 HG009490. D.E.B. is supported by the NIDDK (R03DK109232), NHLBI (DP2OD022716, P01HL32262), Burroughs Wellcome Fund, Doris Duke Charitable Foundation and St. Jude Children’s Research Hospital Collaborative Research Consortium. L.P. is supported by NHGRI (R00HG008399), DARPA HR0011-17-2-0042, and the Centers for Excellence in Genomic Science of the National Institutes of Health under award number RM1HG009490 through a New Collaborator Grant subaward.

Author information

Authors and Affiliations

  1. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Kendell Clement, Matthew C. Canver, Rick Farouni, Jonathan Y. Hsu, Daniel E. Bauer & Luca Pinello

  2. Molecular Pathology Unit, Center for Cancer Research and Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA

    Kendell Clement, Matthew C. Canver, Jason M. Gehrke, Rick Farouni, Jonathan Y. Hsu, J. Keith Joung & Luca Pinello

  3. Department of Pathology, Harvard Medical School, Boston, MA, USA

    Kendell Clement, Matthew C. Canver, Jason M. Gehrke, Rick Farouni, Jonathan Y. Hsu, J. Keith Joung & Luca Pinello

  4. Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Holly Rees & David R. Liu

  5. Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA

    Holly Rees & David R. Liu

  6. Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA

    Holly Rees & David R. Liu

  7. Division of Hematology/Oncology, Boston Children’s Hospital; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Mitchel A. Cole & Daniel E. Bauer

  8. Department of Pediatrics, Harvard Medical School, Boston, MA, USA

    Daniel E. Bauer

  9. Harvard Stem Cell Institute, Cambridge, MA, USA

    Daniel E. Bauer

Authors
  1. Kendell Clement
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Holly Rees
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew C. Canver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jason M. Gehrke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rick Farouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonathan Y. Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitchel A. Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David R. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Keith Joung
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel E. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Luca Pinello
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.C. and L.P. conceived the project, led the study and wrote the software. K.C. analyzed experimental data. All authors contributed input on measurement and visualization of genome editing outcomes and provided input on the manuscript.

Corresponding authors

Correspondence to Daniel E. Bauer or Luca Pinello.

Ethics declarations

Competing interests

At the time of manuscript preparation, J.M.G. was a consultant for Beam Therapeutics, and now is employed by Beam Therapeutics. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Endcadia, EpiLogic Therapeutics, Pairwise Plants, Poseida Therapeutics and Transposagen Biopharmaceuticals. J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.M.G. and J.K.J. are co-inventors on patents and patent applications that describe gene editing technologies. D.R.L. is a consultant and cofounder of Editas Medicine, Pairwise Plants and Beam Therapeutics, companies that use genome editing.

Additional information

Editor’s note: This article has been peer-reviewed.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–15 and Supplementary Notes 1–4

Supplementary Software

Source Data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clement, K., Rees, H., Canver, M.C. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol 37, 224–226 (2019). https://doi.org/10.1038/s41587-019-0032-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0032-3

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation